Vistagen Therapeutics (VTGN) Income from Continuing Operations (2017 - 2025)
Historic Income from Continuing Operations for Vistagen Therapeutics (VTGN) over the last 13 years, with Q4 2025 value amounting to -$18.9 million.
- Vistagen Therapeutics' Income from Continuing Operations fell 3414.01% to -$18.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$67.0 million, marking a year-over-year decrease of 4173.43%. This contributed to the annual value of -$51.4 million for FY2025, which is 7511.75% down from last year.
- Latest data reveals that Vistagen Therapeutics reported Income from Continuing Operations of -$18.9 million as of Q4 2025, which was down 3414.01% from -$19.4 million recorded in Q3 2025.
- Vistagen Therapeutics' Income from Continuing Operations' 5-year high stood at -$6.2 million during Q1 2021, with a 5-year trough of -$19.8 million in Q2 2022.
- For the 5-year period, Vistagen Therapeutics' Income from Continuing Operations averaged around -$12.4 million, with its median value being -$12.5 million (2021).
- Per our database at Business Quant, Vistagen Therapeutics' Income from Continuing Operations plummeted by 28798.59% in 2021 and then surged by 6509.46% in 2023.
- Vistagen Therapeutics' Income from Continuing Operations (Quarter) stood at -$10.5 million in 2021, then rose by 7.34% to -$9.8 million in 2022, then surged by 34.95% to -$6.4 million in 2023, then crashed by 121.87% to -$14.1 million in 2024, then tumbled by 34.14% to -$18.9 million in 2025.
- Its Income from Continuing Operations was -$18.9 million in Q4 2025, compared to -$19.4 million in Q3 2025 and -$15.1 million in Q2 2025.